The acquisition will provide the Japanese group with greater ability to create innovative drugs for diseases that require greater attention from the scientific community.
Astellas Pharma remains determined to diversify its business area. Last year, the company has 
reorganized around four areas of interest and with the acquisition of Audentes Therapeutics for 3,000 million dollars (2,693 million euros) opened a fifth, dedicated to genetic regulation.
Astellas' commitment to the acquisition of the biotech company was determined. In fact, it paid a 110% premium to the share price at the close of Monday's session. The large amount for which the purchase has been formalized suggests that several companies may have shown interest in Audentes, as reported by FierceBiotech.
“Accelerating early-stage scientific innovation in areas such as cell and gene therapy is a strategic approach for Astellas and aligns perfectly with the mission of our launch platform for new life sciences and biotech companies,” he said. Kenji. Yasukawa, president of Astellas.
